MALVERN, PA. & MONTREAL, QC, December 3 /CNW/ - Gemin X announced today that results of several clinical and preclinical studies of its lead anti-cancer candidate obatoclax (GX15-070) will be presented at the 49th annual meeting of the American Society of Hematology (ASH) in Atlanta, GA. Obatoclax is a novel, small molecule candidate in Phase 2 trials in multiple cancer indications that is specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.
